Get the Stockscreener App
232.30
1.73%
3.94
After Hours:
232.30
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $232.30, with a volume of 105.66K.
It is up +1.73% in the last 24 hours and up +16.39% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$228.36
Open:
$228.36
24h Volume:
105.66K
Relative Volume:
0.49
Market Cap:
$4.65B
Revenue:
$268.09M
Net Income/Loss:
$124.45M
P/E Ratio:
39.81
EPS:
5.8347
Net Cash Flow:
$38.05M
1W Performance:
-0.01%
1M Performance:
+16.39%
6M Performance:
+22.02%
1Y Performance:
+118.43%
1-Day Range:
$228.36
$233.06
1-Week Range:
$220.06
$236.22
52-Week Range:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
232.30 | 4.58B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand CEO joins Palvella chief at May 6 investor fireside chat - Stock Titan
Ligand to Participate in May Investor Conferences - Yahoo Finance
Ligand to buy XOMA Royalty for $39/share - MSN
CLO Andrew Reardon nets 5,000-share sale at Ligand (NASDAQ: LGND) - Stock Titan
Ligand Pharmaceuticals CLO Andrew Reardon sells $1.16m in stock - Investing.com
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing - The Motley Fool
MSN Money - MSN
LGND PE Ratio & Valuation, Is LGND Overvalued - Intellectia AI
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
Ligand Pharma Ends TR‑Beta License With Viking Therapeutics - The Globe and Mail
LGND (NASDAQ) Rule 144 notice lists 467 common shares and dated sales - Stock Titan
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND) - Stock Titan
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ligand bets on royalty growth with XOMA buyout worth over $700 million - MSN
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event - Stock Titan
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $289 - GuruFocus
HC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals is buying Xoma for nearly $740 million - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownHere's Why - MarketBeat
LGND: XOMA Buy Adds 100+ Assets - Smartkarma
Moody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ - MSN
LGND Maintained by RBC Capital -- Price Target Raised to $252 - GuruFocus
Ligand to acquire XOMA Royalty - The Pharma Letter
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount - Yahoo Finance
RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating - Moomoo
RBC Capital raises Ligand Pharma stock price target on XOMA deal - Investing.com Canada
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - Yahoo Finance
Why Ligand's $739M Xoma buy matters for growth - Axios
BofA raises Ligand Pharma stock price target on XOMA acquisition - Investing.com
Stifel raises Ligand Pharma stock price target on XOMA acquisition - Investing.com UK
BofA raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com Canada
Stifel raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com India
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million - 104.1 WIKY
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
Ligand Pharmaceuticals Incorporated entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $470 million from BVF Partners L.P. and others. - marketscreener.com
Ligand Pharmaceuticals Acquires Zoma for $740 Million - GuruFocus
Ligand Pharmaceuticals (LGND) to Acquire Xoma Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals stock hits 52-week high at 240.25 USD By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs - TradingView
Ligand strikes $739M deal for Xoma Royalty - Axios
Ligand Pharmaceuticals to Acquire Xoma Royalty for 739 Million Dollars - HarianBasis.co
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal - Stock Titan
Ligand Pharmaceuticals (LGND) to Acquire XOMA Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals buying Xoma Royalty for $739 million - Yahoo Finance
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):